On July 20th 2007, Aremis became part of IMS Health. This is an exciting development that will enable us to accelerate our provision and commitment to quality services for the pharmaceutical and health care industry; health economics and outcomes research expertise is seen by us as a key area.
AREMIS has wide experience in strategic consultancy, health economics, observational studies and health policy at a local, national and international level and number as customers big pharma and biotech companies; public and private health institutions and patients' associations.
Following this acquisition IMS now offers consulting expertise in the following areas to support the use of outcomes measures in health care resource allocation decisions:
-
HEOR strategy development
-
Cost-effectiveness studies
-
Budget impact analyses
-
Observational studies
-
Incidence and prevalence
-
Health economic model development and evaluation
-
Cost-of-illness studies and disease management models
-
Health and budget impact analyses
-
Willingness to pay surveys
-
Global and local understanding of health care practices and policies
-
Design and analysis of prospective studies
We are confident the combined capabilities and expertise of Aremis and IMS Health will provide an even stronger, broader range of solutions to support their businesses.
If you have any questions about this development, please do not hesitate to call us on the number below, or visit the Aremis website.
| Annie Chicoye | Tina Lambert |
| IMS HEOR Tel: +44(0)20 3075 5000 |
IMS HEOR Tel: +44(0)20 3075 5000 |